Account
Sign In
Home
Daily Diary
Asset Class
Fixed Income
Currencies
US Equity
Specialty
Global Equity & Income
Commodities
Sectors
Healthcare
Financial Services
Basic Materials
Consumer Cyclicals
Telecom Services
Energy
Transportation
Consumer Staples
Industrials
Utilities
Technology
Real Estate
Latest
Columnist Conversation
Video
Street Notes
Authors
Bruce Kamich
Jim Cramer
Jim "Rev Shark" DePorre
Brian Sozzi
Helene Meisler
Jonathan Heller
Roger Arnold
- See All -
Options
RMPIA
Switch Product
Action Alerts PLUS
Daily Swing Trade Archive
Income Seeker
Quant Ratings
Retirement
Stocks Under $10
TheStreet
Top Stocks
Trifecta Stocks
Information Provided By:
Visit TheFly.com
TheFly.com Free Trial
Fly News Breaks for February 5, 2020
NBIX
Get Breaking Institutional Stock News For
Free
with a 14 day trial
16:31 EST Neurocrine initiated with a Neutral at Mizuho
Feb 5, 2020 | 16:31 EDT
Mizuho initiated coverage of Neurocrine with a Neutral rating and $107 price target.
News For NBIX From the Last 2 Days
NBIX
Get Breaking Institutional Stock News For
Free
with a 14 day trial
Tesla, Airbnb upgraded: Wall Street's top analyst calls
Apr 24, 2024 | 09:36 EDT
NBIX
Get Breaking Institutional Stock News For
Free
with a 14 day trial
Wells Fargo upgrades Neurocrine with pipeline 'turning a corner'
Apr 23, 2024 | 16:41 EDT
NBIX
Get Breaking Institutional Stock News For
Free
with a 14 day trial
Wells Fargo gets more bullish on Neurocrine, upgrades shares
Apr 23, 2024 | 16:09 EDT
NBIX
Get Breaking Institutional Stock News For
Free
with a 14 day trial
Neurocrine NBI-1065845 results 'look potentially promising,' says RBC Capital
Apr 23, 2024 | 10:29 EDT
NBIX
Get Breaking Institutional Stock News For
Free
with a 14 day trial
Neurocrine's NBI-1065845 shows efficacy in major depressive disorder
Apr 23, 2024 | 07:08 EDT